S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

Anika Arthritis Treatment Approval Brings All-Time Highs, Maybe More to Come

Photo of Cgblaine22
By Cgblaine22 Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

knees
Thinkstock
Shares of biotechnology company Anika Therapeutics Inc. (NASDAQ: ANIK) soared to an all-time high Wednesday after the company said the U.S. Food and Drug Administration (FDA) had approved its drug to treat pain and improve joint mobility in patients with osteoarthritis of the knee.

The company said the drug, called Monovisc, will be marketed by DePuy Synthes, a unit of Johnson & Johnson (NYSE: JNJ). Anika will receive a $5 million payment when DePuy Synthes makes its first sale of the drug. It will receive additional payments and royalty fees in the future as well.

Monovisc treats pain and improves joint mobility. It is injected into the synovial fluid of a patient’s knee. It has been available since 2008 in Europe, Canada, the United Kingdom and other countries in Europe, the Middle East and Asia.

The shares were up $15.84, or 46%, to $50.31, after hitting an intraday peak of $51.95 right after the open. Formed in 1992, Anika has been growing steadily in recent years, with sales hitting $71 million in 2012, up from $40 million in 2009.

Fourth-quarter results for 2013 are due after Wednesday’s close, with analysts expecting $0.42 a share in earnings, unchanged from a year ago, on revenue of $21.1 million, down slightly.

Photo of cgblaine22
About the Author cgblaine22 →

Charley Blaine is a veteran financial journalist. He wrote about markets and edited personal finance articles at MSN Money. He was editor of Family Money magazine and business/financial editor at The Times-Picayune and a Money reporter at USA Today.

Continue Reading

Douglas A. McIntyre |

The Eleven Most Implanted Medical Devices In America

Implanted medical devices are one of the most profitable businesses of the U.S. healthcare industry. While many devices help extend…
Wedbush Has 3 Biotech Stocks to Buy With Massive Upside Potential
Lee Jackson |

Wedbush Has 3 Biotech Stocks to Buy With Massive Upside Potential

Here are three biotech companies that not only have data that could prove to be huge, but their shares have…
New Osteoarthritis Treatment Could Precipitate Another Blockbuster Drug
Chris Lange |

New Osteoarthritis Treatment Could Precipitate Another Blockbuster Drug

Teva and Regeneron both saw handy gains on Thursday after the companies posted positive topline results from their late-stage trial…
Chris Lange |

Is Ampio at Risk of Imploding?

Ampio announced Monday that a Phase 3 for the treatment pain due to osteoarthritis of the knee did not reach…
6 Speculative Biotech Stocks With 50% to 250% Potential Upside
Jon C. Ogg |

6 Speculative Biotech Stocks With 50% to 250% Potential Upside

This year is shaping up to be a stellar one for biotech. Investors are looking for growth and upside, and…
Wednesday’s Top 5 Biopharma Movers
Chris Lange |

Wednesday’s Top 5 Biopharma Movers

A few biotech and pharma companies were on the move Wednesday, some making absolutely massive gains on the day, giving…
Paul Ausick |

J&J, Bayer Fail to Gain FDA Approval for Blood Thinner

ThinkstockThe U.S. Food and Drug Administration (FDA) last night rejected an application from Johnson & Johnson (NYSE: JNJ) and Germany’s…
Douglas A. McIntyre |

ISIS Scores On J&J Collaboration & Milestones (ISIS, JNJ)

ISIS Pharmaceuticals Inc. (NASDAQ:ISIS) is trading up pre-market on new that it entered a broad collaboration with Ortho-McNeil, a Johnson…
Will a Recent Rheumatoid Arthritis Drug Approval See Rekindled Interest?
Jon C. Ogg |

Will a Recent Rheumatoid Arthritis Drug Approval See Rekindled Interest?

Rheumatoid arthritis is an autoimmune disease that attacks tissues within the joints, and it is a major target of U.S.…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618